发现了用于癌症免疫治疗的强效PARP7抑制剂
相关实验视频
Updated: Jun 25, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
290
Jieping Yang1, Beibei Liu1, Wenxin Yan1
1Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
Bioorganic chemistry
|May 23, 2024
概括
一种新型的Poly (ADP-ribose) 聚合酶7 (PARP7) 抑制剂,XLY-1,增强了I型干扰素信号传递. 这种强大的抑制剂通过恢复免疫信号和促进T细胞透到瘤组织中,表现出显著的抗瘤活性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 多 (ADP-ribose) 聚合酶7 (PARP7) 对于免疫功能至关重要.
- 在各种癌症中,PARP7被上调,抑制I型干扰素信号传递.
- 抑制PARP7活性可以恢复I型干扰素对抗瘤免疫的信号传递.
研究的目的:
- 确定和描述用于癌症免疫治疗的新型PARP7抑制剂.
- 评估已识别的抑制剂XLY-1的抗瘤疗效.
主要方法:
- 在体外酶抑制试验中测定XLY-1和RBN-2397对PARP7和PARP1.1的IC50值.
- 试管体内机制研究,以评估XLY-1对I型干扰素信号传递的影响.
- 在体内药理动力学实验评估XLY-1的瘤生长抑制 (TGI) 和对免疫信号和T细胞透的影响.
主要成果:
- XLY-1 显示出强大的 PARP7 抑制 (IC50 = 0.6 nM),明显超过了 RBN-2397 (IC50 = 6.0 nM).
- XLY-1对PARP1表现出弱抑制 (IC50> 1.0μM),这表明具有选择性.
- 在体外研究证实XLY-1增强了I型干扰素信号传递.
- 在体内,XLY-1显著抑制瘤生长 (76.5%TGI) 并恢复I型干扰素信号传递,同时促进T细胞透.
结论:
- XLY-1是一种强效和选择性的PARP7抑制剂,具有有前途的抗瘤活性.
- 通过增强I型干扰素信号传递和T细胞反应,XLY-1显示出作为癌症免疫治疗新型药物的潜力.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer Vaccines
355
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
355
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

